ORIC Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Form 8-K reporting its entry into a securities purchase agreement on June 24, 2023. The company is a clinical-stage biopharmaceutical issuer. The filing concerns a private placement of common stock and pre-funded warrants; it does not provide financial statements or operating results for a reporting period.
Financing and Key Financial Terms
- ORIC agreed to sell 9,285,710 common shares at $7.00 per share.
- ORIC also agreed to sell pre-funded warrants exercisable for 2,857,142 common shares at $6.9999 per warrant.
- The warrants have an exercise price of $0.0001 per share, are immediately exercisable, and remain exercisable until fully exercised.
- Aggregate gross proceeds are expected to be approximately $85 million, before offering expenses.
- The transaction was expected to close on June 27, 2023, subject to customary closing conditions.
- Net proceeds are intended to fund research and development of clinical-stage product candidates and research programs, as well as working capital and general corporate purposes.
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balance, liquidity runway, or other operating financial metrics.
Material Changes and Securities Terms
- The private placement is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The securities were not registered and may not be resold in the United States absent registration or an applicable exemption.
- Purchasers and the company’s executive officers and directors agreed to transfer restrictions, generally lasting until the earlier of the initial data readout from the Phase 1b ORIC-114 trial after June 24, 2023, or December 31, 2023, subject to exceptions.
- ORIC agreed to file a resale registration statement by January 31, 2024, subject to specified exceptions, use commercially reasonable efforts to have it declared effective, and keep it effective for up to two years.
- Warrant exercises are subject to a 9.99% beneficial ownership limitation, which may be increased or decreased to no more than 19.99% with at least 61 days’ prior notice.
Outlook, Risks, and Unusual Items
Completion of the financing and the anticipated use of proceeds are forward-looking matters dependent on market conditions and customary closing conditions. The financing will increase shares outstanding through issued shares and potentially through warrant exercises, resulting in dilution to existing stockholders. The filing also identifies risks related to resale registration, securities-law restrictions, and the company’s ability to advance its clinical programs. No revenue guidance or clinical efficacy guidance is provided in the filing.
Important Facts for Investors to Verify
- Whether the private placement closed on June 27, 2023 and the actual net proceeds after expenses.
- The final number of common shares outstanding after the financing and any subsequent warrant exercises.
- The status and timing of the resale registration statement.
- The company’s cash balance, quarterly cash burn, debt, and liquidity runway in subsequent periodic filings.
- Progress and initial data from the Phase 1b ORIC-114 clinical trial.
- The complete terms of the securities purchase agreement and pre-funded warrants filed as Exhibits 10.1 and 4.1.